Merck KGaA
OTC:MKKGY
Relative Value
The Relative Value of one
MKKGY
stock under the Base Case scenario is
hidden
USD.
Compared to the current market price of 28.78 USD,
Merck KGaA
is
hidden
.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Multiples Across Competitors
MKKGY Competitors Multiples
Merck KGaA Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| DE |
|
Merck KGaA
OTC:MKKGY
|
52.9B USD | 2.5 | 17.9 | 10.3 | 15.3 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
964.4B USD | 15.3 | 48.4 | 32.6 | 34.7 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
573.2B USD | 6.1 | 21.4 | 14.9 | 18.3 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
281.7B CHF | 4.6 | 30.1 | 12.7 | 14.8 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
297.7B USD | 4.6 | 16.5 | 10.3 | 12.1 | |
| CH |
|
Novartis AG
SIX:NOVN
|
228.8B CHF | 5.3 | 21.3 | 13.1 | 16.9 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
217.3B GBP | 5.2 | 32 | 15.3 | 22.4 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 333.1 | 835.4 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.3T DKK | 4.2 | 12.7 | 9.3 | 11 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153B USD | 2.4 | 19.7 | 7.3 | 9.8 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
125.7B USD | 2.6 | 20.8 | 7.3 | 9.6 |